U.S. Ambassador to India Sergio Gor said Wednesday that the U.S.-India trade agreement is 99% finalized [2].
The announcement signals a critical shift in supply-chain resilience for the U.S. healthcare system and a deepening strategic alliance between the two nations.
Speaking at a public event in Hyderabad and a forum in Mumbai, Gor said the partnership is built on mutual reliability. He highlighted the role of the Indian pharmaceutical industry in maintaining American health standards. "India supplies nearly 40% of America’s generic medicines," Gor said [1].
Gor linked this pharmaceutical cooperation to the new U.S. initiative known as "Pax Silica." According to the ambassador, India was among the first nations invited to participate in the initiative, which aims to foster deeper cooperation in technology and pharma sectors [1].
Despite the progress, a small portion of the trade deal remains undecided. Gor said the agreement is 99% there, with only 1% left to resolve [3]. He did not specify the exact nature of the remaining sticking point but emphasized the strength of the current relationship.
"We trust India," Gor said [1].
The ambassador's remarks underscore a broader effort to secure the U.S. medical supply chain by reducing dependence on other regions and leveraging India's manufacturing capacity. The finalized trade pact is expected to streamline these processes, and formalize the strategic partnership across multiple industrial sectors [2].
“"The trade agreement is 99% there, only 1% left to resolve."”
The near-completion of this trade pact, combined with India's significant share of the U.S. generic drug market, indicates a strategic pivot toward 'friend-shoring.' By integrating India into the Pax Silica initiative, the U.S. is attempting to institutionalize a high-tech and medical supply chain that is less vulnerable to geopolitical volatility in East Asia.
